dc.contributor.author |
He, WS |
en |
dc.contributor.author |
Bishop, Karen |
en |
dc.date.accessioned |
2016-08-23T04:08:22Z |
en |
dc.date.issued |
2016 |
en |
dc.identifier.citation |
Expert Review of Molecular Diagnostics, 2016, 16 (8), pp. 1 - 14 |
en |
dc.identifier.issn |
1473-7159 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/30113 |
en |
dc.description.abstract |
Introduction: We are yet to identify an accurate, precise and non-invasive biomarker for the detection of prostate cancer. It would undoubtedly be useful to have a reliable and cost-effective biomarker to inform clinical practice, in order to make a non-invasive diagnosis and to predict risk of progression to aggressive prostate cancer. Since the detection of cell-free-circulating-tumor DNA in the body fluids of prostate cancer patients, a number of studies have been conducted to assess diagnostic and/or prognostic information. Areas covered: In this literature review we evaluate the utility of cell-free-circulating-tumor-DNA for the development of a diagnostic and/or prognostic tool for prostate cancer. In addition, we identify potential areas for future research. Results from both quantitative and qualitative studies are presented. Expert commentary: Evidence for the suitability of a panel of DNA methylation markers for the non-invasive diagnosis of prostate cancer is strong. This panel would likely include the assessment of methylation status in gene promoter regions within the EDNR, GSTP1 and MDR genes. TIMP3 and APC show potential as diagnostic markers and should be further researched. Similarly, quantitation of cell-free-circulating-tumor-DNA in blood and urine requires further investigation. |
en |
dc.description.uri |
http://www.tandfonline.com/toc/iero20/current |
en |
dc.publisher |
Expert Reviews |
en |
dc.relation.ispartofseries |
Expert Review of Molecular Diagnostics |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1473-7159/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1080/14737159.2016.1197121 |
en |
pubs.issue |
8 |
en |
pubs.begin-page |
839 |
en |
pubs.volume |
16 |
en |
dc.identifier.pmid |
27254598 |
en |
pubs.author-url |
http://www.tandfonline.com/doi/full/10.1080/14737159.2016.1197121 |
en |
pubs.end-page |
852 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
en |
pubs.elements-id |
536934 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
dc.identifier.eissn |
1744-8352 |
en |
pubs.record-created-at-source-date |
2016-08-23 |
en |
pubs.dimensions-id |
27254598 |
en |